Abstract 3536: Genetic validation of an ATM immunohistochemistry assay for genomic and clinical-pathologic characterization of primary prostate cancers with ATM loss

MLA

Emmanuel S. Antonarakis, et al. “Abstract 3536: Genetic Validation of an ATM Immunohistochemistry Assay for Genomic and Clinical-Pathologic Characterization of Primary Prostate Cancers with ATM Loss.” Cancer Research, vol. 80, Aug. 2020, p. 3536. EBSCOhost, https://doi.org/10.1158/1538-7445.am2020-3536.

APA

Emmanuel S. Antonarakis, Jessica L. Hicks, Harsimar B. Kaur, Kirsten Timms, William B. Isaacs, Jerry S. Lanchbury, Colin C. Pritchard, Tamara L. Lotan, & Angelo M. De Marzo. (2020). Abstract 3536: Genetic validation of an ATM immunohistochemistry assay for genomic and clinical-pathologic characterization of primary prostate cancers with ATM loss. Cancer Research, 80, 3536. https://doi.org/10.1158/1538-7445.am2020-3536

Chicago

Emmanuel S. Antonarakis, Jessica L. Hicks, Harsimar B. Kaur, Kirsten Timms, William B. Isaacs, Jerry S. Lanchbury, Colin C. Pritchard, Tamara L. Lotan, and Angelo M. De Marzo. 2020. “Abstract 3536: Genetic Validation of an ATM Immunohistochemistry Assay for Genomic and Clinical-Pathologic Characterization of Primary Prostate Cancers with ATM Loss.” Cancer Research 80 (August): 3536. doi:10.1158/1538-7445.am2020-3536.